JP6345645B2 - 横隔膜機能を向上させるための方法 - Google Patents

横隔膜機能を向上させるための方法 Download PDF

Info

Publication number
JP6345645B2
JP6345645B2 JP2015503681A JP2015503681A JP6345645B2 JP 6345645 B2 JP6345645 B2 JP 6345645B2 JP 2015503681 A JP2015503681 A JP 2015503681A JP 2015503681 A JP2015503681 A JP 2015503681A JP 6345645 B2 JP6345645 B2 JP 6345645B2
Authority
JP
Japan
Prior art keywords
pyrazin
imidazo
alkyl
prop
enyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015503681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516957A (ja
JP2015516957A5 (cg-RX-API-DMAC7.html
Inventor
ジェフリー アール． ジャスパー，
ジェフリー アール． ジャスパー，
ファディー マリック，
ファディー マリック，
ダレン ティー． フウィー，
ダレン ティー． フウィー，
Original Assignee
サイトキネティックス， インコーポレイテッド
サイトキネティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイトキネティックス， インコーポレイテッド, サイトキネティックス， インコーポレイテッド filed Critical サイトキネティックス， インコーポレイテッド
Publication of JP2015516957A publication Critical patent/JP2015516957A/ja
Publication of JP2015516957A5 publication Critical patent/JP2015516957A5/ja
Application granted granted Critical
Publication of JP6345645B2 publication Critical patent/JP6345645B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015503681A 2012-04-02 2013-04-01 横隔膜機能を向上させるための方法 Expired - Fee Related JP6345645B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261619261P 2012-04-02 2012-04-02
US61/619,261 2012-04-02
PCT/US2013/034824 WO2013151938A1 (en) 2012-04-02 2013-04-01 Methods for improving diaphragm function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018098858A Division JP2018131460A (ja) 2012-04-02 2018-05-23 横隔膜機能を向上させるための方法

Publications (3)

Publication Number Publication Date
JP2015516957A JP2015516957A (ja) 2015-06-18
JP2015516957A5 JP2015516957A5 (cg-RX-API-DMAC7.html) 2016-06-02
JP6345645B2 true JP6345645B2 (ja) 2018-06-20

Family

ID=49300969

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015503681A Expired - Fee Related JP6345645B2 (ja) 2012-04-02 2013-04-01 横隔膜機能を向上させるための方法
JP2018098858A Ceased JP2018131460A (ja) 2012-04-02 2018-05-23 横隔膜機能を向上させるための方法
JP2020104620A Pending JP2020147607A (ja) 2012-04-02 2020-06-17 横隔膜機能を向上させるための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018098858A Ceased JP2018131460A (ja) 2012-04-02 2018-05-23 横隔膜機能を向上させるための方法
JP2020104620A Pending JP2020147607A (ja) 2012-04-02 2020-06-17 横隔膜機能を向上させるための方法

Country Status (15)

Country Link
US (2) US20150065525A1 (cg-RX-API-DMAC7.html)
EP (1) EP2834269A4 (cg-RX-API-DMAC7.html)
JP (3) JP6345645B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160046693A (cg-RX-API-DMAC7.html)
CN (2) CN108553467A (cg-RX-API-DMAC7.html)
AU (2) AU2013243671B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014024552A2 (cg-RX-API-DMAC7.html)
CA (1) CA2868507A1 (cg-RX-API-DMAC7.html)
EA (1) EA031183B1 (cg-RX-API-DMAC7.html)
HK (1) HK1206364A1 (cg-RX-API-DMAC7.html)
IL (2) IL234885A0 (cg-RX-API-DMAC7.html)
MX (1) MX354965B (cg-RX-API-DMAC7.html)
PH (1) PH12014502217A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201406270YA (cg-RX-API-DMAC7.html)
WO (1) WO2013151938A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US10272082B2 (en) 2011-07-13 2019-04-30 Cytokinetics, Inc. Combination ALS therapy
SG10201704166RA (en) * 2012-04-11 2017-06-29 Cytokinetics Inc Improving resistance to skeletal muscle fatigue
EP4534538A3 (en) 2012-12-07 2025-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
AU2014229313B2 (en) 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA2932757C (en) 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
RS63018B1 (sr) 2014-04-29 2022-04-29 Cytokinetics Inc Metode za smanjenje opadanja vitalnog kapaciteta
RU2719583C2 (ru) 2014-06-05 2020-04-21 Вертекс Фармасьютикалз Инкорпорейтед Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
US9987279B2 (en) * 2014-09-09 2018-06-05 Astellas Pharma Inc. Pharmaceutical composition for prevention and/or treatment of urinary incontinence
JP2018516254A (ja) 2015-05-29 2018-06-21 ファイザー・インク バニン１酵素の阻害薬としての新規なヘテロ環化合物
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
CN113666938A (zh) 2016-02-12 2021-11-19 细胞动力学股份有限公司 四氢异喹啉衍生物
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
WO2020254343A1 (en) * 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Digital biomarker
CN114007495A (zh) 2019-06-19 2022-02-01 豪夫迈·罗氏有限公司 数字生物标志物
BR112022000325A2 (pt) 2019-07-11 2022-03-15 Escape Bio Inc Indazois e azaindazois como inibidores de lrrk2
US11981644B2 (en) 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US20240382564A1 (en) * 2023-04-17 2024-11-21 Allysta Pharmaceuticals, Inc. Methods and Compositions for Treating Muscular Dystrophy and Memory Impairment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) * 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
AU2001268149B2 (en) * 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
CN1283793C (zh) * 2002-06-03 2006-11-08 北京大学 具有骨骼肌刺激活性和免疫调节作用的趋化素样因子超家族
EP1651638A1 (en) * 2003-08-08 2006-05-03 Janssen Pharmaceutica N.V. Pyridyl piperazinyl ureas
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
DK2069352T5 (en) * 2006-08-02 2017-04-03 Cytokinetics Inc SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
WO2009023193A1 (en) * 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
NL2001694C2 (en) * 2008-06-18 2009-12-22 Nasophlex B V Ear stimulator for producing a stimulation signal to an ear.
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos

Also Published As

Publication number Publication date
MX354965B (es) 2018-03-27
HK1206364A1 (en) 2016-01-08
BR112014024552A2 (pt) 2017-09-19
AU2013243671B2 (en) 2017-09-21
JP2015516957A (ja) 2015-06-18
US20170266192A1 (en) 2017-09-21
AU2013243671A1 (en) 2014-10-16
JP2018131460A (ja) 2018-08-23
IL267876B (en) 2021-03-25
MX2014011881A (es) 2016-07-20
SG11201406270YA (en) 2014-10-30
US20150065525A1 (en) 2015-03-05
AU2017272286A1 (en) 2018-01-04
EP2834269A1 (en) 2015-02-11
PH12014502217A1 (en) 2015-01-12
JP2020147607A (ja) 2020-09-17
SG10201701101YA (en) 2017-04-27
CN108553467A (zh) 2018-09-21
EP2834269A4 (en) 2015-12-30
EA031183B1 (ru) 2018-11-30
KR20160046693A (ko) 2016-04-29
CN104379597A (zh) 2015-02-25
AU2017272286B2 (en) 2019-05-09
EA201491605A1 (ru) 2015-03-31
WO2013151938A1 (en) 2013-10-10
IL267876A (en) 2019-09-26
IL234885A0 (en) 2014-12-31
CA2868507A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
JP6345645B2 (ja) 横隔膜機能を向上させるための方法
CN105859712B (zh) 作为nadph氧化酶抑制剂的吡唑并吡啶衍生物
JP6609631B2 (ja) 縮合環ヘテロアリール化合物及びｔｒｋ抑制剤としての用途
JP6535727B2 (ja) 骨格筋疲労に対する耐性を向上させるための方法
JP2022506687A (ja) ピリダジノン化合物およびその使用
WO2014095774A1 (de) Bet-proteininhibitorische dihydropyridopyrazinone
JP2014505091A (ja) ６−シクロブチル−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｐｄｅ９ａ阻害剤としてのその使用
CN107108671A (zh) 作为raf激酶抑制剂的化合物和组合物
TW201831486A (zh) Ｐｄｅ２抑制劑
TW201321353A (zh) 胺基甲酸酯／尿素衍生物
EP3672957A1 (en) Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors
TW202146384A (zh) 取代的氮雜五元環類化合物及其在藥物中的應用
JP7787893B2 (ja) Ｎａｍｐｔモジュレーターとして有用なピラゾール誘導体
HK1261324A1 (en) Methods for improving diaphragm function
WO2025148955A1 (zh) 含有嘌呤环的化合物及其用途
WO2024131265A1 (zh) 用于治疗PI3Kγ介导的疾病的化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160401

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180523

R150 Certificate of patent or registration of utility model

Ref document number: 6345645

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees